What is the DeLLphi-305 Clinical Trial?

At your first visit(s), you will:

• Meet the clinical trial doctor and team at the location of the trial. This may be different from where you have received treatment in the past.
• Review and sign an informed consent to join the DeLLphi-305 clinical trial.
• Complete a general health assessment, including a physical exam, medical history, blood tests, and imaging.
• Have your tumor sampled.*

Approximately 550 participants will be randomly assigned to receive either tarlatamab (investigational drug) in combination with durvalumab (Imfinzi®) or durvalumab alone.

The tarlatamab group will:

• Receive tarlatamab by infusion (in a vein) once a week for the first 3 weeks and then once every 2 weeks afterwards.
• Receive durvalumab by infusion every two weeks or every four weeks, depending on the patient’s weight.
• Attend clinical trial appointments and check-ups to record your progress.

The durvalumab group will:

• Receive durvalumab by infusion every two weeks or every four weeks, depending on the patient’s weight.
• Attend clinical trial appointments and check-ups to record your progress.

You will continue to receive treatment in this clinical trial based on the results of your bloodwork and imaging. The treatment you receive in this trial or your participation in this clinical trial may end if:

1. Your cancer gets worse.
2. You experience serious side-effects from treatment.
3. You decide to stop the trial at any time.

The clinical trial team will schedule a follow-up visit with you approximately 12 weeks after your last trial treatment.

The clinical trial team may follow-up with you by phone or ask you to visit the clinic approximately once every 3 months.